Smoking Cessation Interventions

Cigarette smoking is the leading cause of preventable disease and death despite its known health effects. Although nearly one-half of people who smoke try to quit each year, only up to 1 in 20 who quit without support achieve abstinence for at least six months. Clinical studies have demonstrated that combining pharmacotherapy with effective behavior strategies is significantly more effective than either approach alone. Pharmacotherapies approved by the U.S. Food and Drug Administration for smoking cessation include nicotine replacement therapy, bupropion, and varenicline.
e-Cigarettes are not approved by the U.S. Food and Drug Administration for smoking cessation. Lung cancer screening is recommended for adults 50 to 80 years of age who have a 20-pack-year smoking history and currently smoke or have quit within the past 15 years. Lung cancer screening should be combined with smoking cessation tools and treatment.

The article mischaracterizes the findings [https://doi.org/10.1002/14651858.CD010216.pub7] of the Cochrane Review on Electronic Cigarettes for Smoking Cessation.
“[t]here is HIGH‐certainty evidence that [e-cigarettes] with nicotine increase quit rates compared to [traditional nicotine replacement therapies] and moderate-certainty evidence compared to [e-cigarettes] without nicotine.